Welcome to our dedicated page for YS Biopharma Co., Ltd. Ordinary Shares news (Ticker: YS), a resource for investors and traders seeking the latest updates and insights on YS Biopharma Co., Ltd. Ordinary Shares stock.
YS Biopharma Co., Ltd. (Nasdaq: YS) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering next-generation vaccines and therapeutic biologics for infectious diseases and cancer. Operating in China, the United States, Singapore, and the Philippines, YS Biopharma leverages its proprietary PIKA® immunomodulating technology platform to create innovative solutions for diseases such as rabies, coronavirus, hepatitis B, influenza, and shingles.
The company recently announced changes to its board of directors and key strategic appointments within its wholly-owned subsidiaries in China. Notable changes include the resignation of Mr. Bo Tan and Mr. Shaojing Tong from the board and the appointment of Ms. Chunyuan Wu as the new legal representative and executive director of Beijing Yisheng Biotechnology Co., Ltd.
YS Biopharma is also making significant strides in its financial performance, having fully repaid a $40,000,000 loan, which enhances its financial strength and flexibility. The company continues to advance its product pipeline, achieving positive interim results from a Phase 3 clinical trial of its PIKA Rabies Vaccine, which promises accelerated protection and a shorter regimen compared to conventional vaccines.
In terms of financial health, YS Biopharma reported revenues of RMB438.1 million ($61.9 million) for the first nine months of fiscal 2024. Despite challenges such as supply chain disruptions, the company maintained strong market leadership in rabies vaccines in China, with an estimated double-digit year-over-year growth in product sales during the fourth quarter of fiscal 2024.
Additionally, the company's YS-HBV-002 immunotherapeutic vaccine for chronic hepatitis B virus (HBV) infection received clinical trial approval from the Philippine FDA, with a Phase I clinical trial set to begin in June 2024.
YS Biopharma recently announced it would change its legal name to LakeShore Biopharma Co., Ltd., effective May 28, 2024, to better align with its global market positioning. The company's ordinary shares and warrants will continue to trade on Nasdaq under the new ticker symbols 'LSB' and 'LSBPW', respectively.
For more detailed information, visit investor.ysbiopharma.com.
YS Biopharma Co., Ltd. (NASDAQ: YS) reports preliminary FY2023 revenues of approximately $103 million, reflecting a robust 30% year-over-year growth. Gross margin stands at over 76%, bolstered by strong vaccine sales amidst uncertain economic conditions. Cash and equivalents have increased to $53 million from $42.7 million a year prior. The company maintains approximately 93,058,197 ordinary shares outstanding.
CEO Dr. David Shao highlights the growing demand for their rabies vaccine, anticipating continued revenue growth as social activities resume post-pandemic. The results are preliminary and subject to audit, with caution against relying solely on these figures.
YS Biopharma (Nasdaq: YS) has announced positive interim results from its Phase II study of the PIKA recombinant COVID-19 Vaccine. The vaccine demonstrated superior immunogenicity compared to an inactivated COVID-19 vaccine, achieving statistical significance in both primary and secondary endpoints. Notably, the geometric mean titers (GMT) of neutralizing antibodies against the Omicron variant were significantly higher on Day 7 and Day 14 post-vaccination. The study, conducted across multiple countries, included 300 subjects in Phase II. No significant safety issues were reported, and the results are expected to support further development and eventual publication in peer-reviewed journals.
YS Biopharma, a global biopharmaceutical company, announced the approval of its business combination with Summit Healthcare Acquisition Corp. at a meeting on March 14, 2023. The transaction is expected to close on March 16, 2023, and will result in approximately $36 million of gross proceeds. Following the closure, YS Biopharma's shares and warrants are slated to begin trading on the Nasdaq under the symbols YS and YSBPW on March 17, 2023. YS Biopharma aims to utilize the funds for the clinical development of its PIKA® adjuvanted rabies vaccine and COVID-19 vaccine, enhancing global health initiatives.
FAQ
What is the current stock price of YS Biopharma Co., Ltd. Ordinary Shares (YS)?
What is the market cap of YS Biopharma Co., Ltd. Ordinary Shares (YS)?
What does YS Biopharma specialize in?
Where does YS Biopharma operate?
What is the PIKA® technology platform?
What recent changes have been made to the board of directors?
What are the latest financial achievements of YS Biopharma?
What are the key products in YS Biopharma's pipeline?
Has YS Biopharma received any recent regulatory approvals?
What is the new name of YS Biopharma?
Will the ticker symbol of YS Biopharma change?
How can I get more information about YS Biopharma?
